Introduction {#s1}
============

Chronic obstructive pulmonary disease (COPD) is a critically important international health problem. The prevalence of COPD in Europe has been estimated to range between 4% and 10% \[[@C1], [@C2]\], and between 1994 and 2010, 2 348 184 deaths were attributed to COPD in the European Union \[[@C3]\]. It has been repeatedly suggested that management of the very large number of patients with COPD can be improved by the development and implementation of evidence-based treatment guidelines \[[@C4], [@C5]\].

There are many definitions of clinical guidelines, which may be characterised as: "...systematically developed statements designed to help practitioners and patients decide on appropriate healthcare for specific clinical conditions and/or circumstances" \[[@C6]\]. It has been noted that the difference between a guideline and a statement is based on methodological requirements. For example, an official scientific statement from the European Respiratory Society (ERS) requires a comprehensive scientific review of the literature by an ERS task force, while a clinical practice guideline also includes systematic reviews, grading of the quality of the evidence and grading of recommendation strength \[[@C7], [@C8]\].

In Europe multiple national guidelines for the treatment of COPD exist. It appears important to understand similarities and differences among them and how they might influence patient management in order to improve future guidelines development at both global and national levels. The aim of this review is to carry out a detailed comparison of these guidelines, but not to review them critically.

Methods {#s2}
=======

National guidelines for treatment of COPD published in the past 7 years in the European Union and Russia were identified and retrieved. This included guidelines from the Czech Republic \[[@C9]\], England and Wales \[[@C10]\], Finland \[[@C11], [@C12]\], France \[[@C13]\], Germany \[[@C14]\], Italy \[[@C15]\], Poland \[[@C16]\], Portugal \[[@C17]\], Russia \[[@C18]\], Spain \[[@C19], [@C20]\] and Sweden \[[@C21]\]. Each guideline was reviewed in detail and information about the most important aspects of patient diagnosis, risk stratification and pharmacotherapy was extracted following a standardised process. These included the following: criteria for establishment of a diagnosis of COPD; evaluations used for determination of disease severity and future risk (primarily for exacerbations); definition of patient subgroups employed to guide decisions with respect to initial treatment; treatment goals for patients with stable COPD; choices for initial disease management in different patient subgroups; the role of combination therapy with long-acting β~2~-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs), including fixed combinations of these agents; criteria for the use of inhaled corticosteroids (ICS); additional treatments that might be employed for treatment of patients with stable COPD; and the influence of comorbidities on COPD treatment decisions. Extracted information was tabulated for comparison.

Results {#s3}
=======

Diagnostic criteria {#s3a}
-------------------

The criterion defining airflow obstruction used for the diagnosis of COPD in most national guidelines was a post-bronchodilator forced expiratory volume in 1 s (FEV~1~) to forced vital capacity (FVC) ratio \<70% (England and Wales, France, Germany, Finland, Portugal and Russia). The guidelines from the Czech Republic, Italy, Poland and Sweden all specified a post-bronchodilator FEV~1~/FVC ratio less than the lower limit of normal (LLN) (*i.e.* below the 5th percentile for age, sex and height). The Spanish guidelines use the fixed ratio as the criterion for diagnosis, except in patients aged \<50 years and \>70 years, for whom the LLN is recommended.

Stratification of disease severity and prediction of future risk {#s3b}
----------------------------------------------------------------

Guidelines from the Czech Republic, England and Wales, France, Germany, Poland, Portugal, Russia and Sweden stratified patients on the basis of the degree of airflow limitation into the four stages set forth in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy, as follows. Stage 1 (mild): FEV~1~ ≥80% predicted; stage 2 (moderate): FEV~1~ 50--79% pred; stage 3 (severe): FEV~1~ 30--49% pred; and stage 4 (very severe): FEV~1~ \<30% pred \[[@C22]\]. The Italian guidelines combined stage 3 and stage 4 in a single "severe" category. The guidelines from Finland identified patients as low risk (FEV~1~ ≥50% pred) and high risk (FEV~1~ \<50% pred) and provided a separate tool for assessing severity of airflow obstruction according to GOLD strategy as well as assessing severity of full clinical presentation. The Spanish guidelines did not consider FEV~1~ alone to categorise patients\' severity, but rather used the BODE (body mass index, airflow obstruction, dyspnoea and exercise capacity) index \[[@C23]\] or BODEx (replaces exercise with exacerbations) \[[@C24]\] for patient stratification. With the BODE index, 0--2 is considered mild COPD, 3--4 moderate, 5--6 severe and ≥7 very severe ([table 1](#TB1){ref-type="table"}). TABLE 1Stratification of chronic obstructive pulmonary disease (COPD) severity/future risk**Severity of airflow limitationSymptom severityExacerbation riskCzech Republic**GOLD stages 1, 2, 3 and 4mMRC or CATLow risk: 0--1 exacerbationsHigh risk: ≥2 exacerbations**England and Wales^\#^**FEV~1~/FVC \<70% pred **and**\
Mild: FEV~1~ ≥80% pred; moderate: FEV~1~ 50--79% pred; severe:\
FEV~1~ 30--49% pred; very severe:\
FEV~1~ \<30% predPresence of systemic symptoms BMI\
Health status: measure not specified (CAT in NICE quality standard) Exercise capacity (*e.g.* 6-min walking distance)\
*P*~aO~2~~Not specified**Finland**Low risk: FEV~1~ ≥50% pred\
High risk: FEV~1~ \<50% pred^¶^CAT score \<10 or ≥10High risk: ≥2 exacerbations or one leading to hospitalisation in the past year**France**GOLD stages 1, 2, 3 and 4mMRC Episodic *versus* daily occurrence of dyspnoea on exerciseHistory of exacerbations (≥2)**Germany**GOLD stages 1, 2, 3 and 4Not graded or used for assessmentNot graded or used for assessment**Italy**Mild: FEV~1~ ≥80% pred; moderate: FEV~1~ \<80% pred and ≥50% pred; severe: FEV~1~ \<50% predNone statedNone stated**Poland**Mild: FEV~1~ ≥80% pred; moderate: FEV~1~ \<80% pred and ≥50% pred; severe: FEV~1~ ≥30% pred and \<50% pred; very severe: FEV~1~ \<30% predmMRC or CATHigh risk: FEV~1~ \<50% pred, **or** ≥2 exacerbations treated with antibiotics\
or 1 hospitalisation due to exacerbation within past 12 months**Portugal**GOLD stages 1, 2, 3 and 4\
Overall: GOLD A, B, C and D classification usedmMRC or CATLow risk: 0--1 moderate exacerbations High risk: ≥2 moderate or ≥1 severe exacerbation**Russia**Mild: FEV~1~ ≥80% pred; moderate: FEV~1~ \<80% pred and ≥50% pred; severe: FEV~1~ ≥30% pred and \<50% pred; very severe: FEV~1~ \<30% predmMRC, CAT or CCQHigh risk: according to GOLD 2011 classification (high risk ≥2 exacerbations or ≥1 hospitalisation per year)**Spain**GOLD stages 1, 2, 3 and 4CATLow risk: 0--1 exacerbations High risk: ≥2 exacerbations**Sweden**FEV~1~CAT, CCQ or mMRCNumber per year[^1]

Most guidelines considered symptom severity. Those from the Czech Republic divided patients into groups with COPD assessment test (CAT) scores \<10 and ≥10 or modified Medical Research Council (mMRC) dyspnoea scores of 0 or ≥1; those from Finland divided groups into those with CAT \<10 and ≥10; those from Poland and Portugal considered CAT and mMRC scores; those from Russia and Sweden employed CAT, mMRC and clinical COPD questionnaire (CCQ) scores; those from Spain employed CAT scores as a measure of disease control at each level of severity \[[@C25]\]; and those from France divided patients on the basis of episodic or daily symptoms and mMRC scores to establish the indications for short- *versus* long-acting bronchodilators. The guidelines from England and Wales recommend evaluation using the mMRC dyspnoea scale, presence of systemic symptoms, body mass index, health status (measured by CAT), exercise capacity (6-min walking distance) and oxygenation as expressed arterial oxygen tension for a more detailed determination of disease severity if necessary ([table 1](#TB1){ref-type="table"}).

Recognition of patient subtypes or phenotypes {#s3c}
---------------------------------------------

There was variability across national guidelines with respect to the identification of patient subtypes, and this may be related, at least in part, to the times at which different guidelines were published. For example, the oldest guidelines included in the analysis were from Germany and do not consider phenotypes, while more recent guidelines generally recognise multiple patient phenotypes. The classic phenotypes of chronic bronchitis and emphysema were recognised in recommendations from the Czech Republic, England and Wales, Poland, Russia, Spain and Sweden (bronchitic only) ([table 2](#TB2){ref-type="table"}). TABLE 2Patient phenotypes/groups to guide treatment decisions**Use of phenotypes/groupsType 1Type 2Type 3Type 4Czech Republic^\#^**YesBronchitic: productive cough over ≥3 months in ≥2 consecutive yearsEmphysematous: absence of productive cough and signs of emphysemaFrequent exacerbator: ≥2 per year treated\
with antibiotics or corticosteroidsCOPD--asthma overlap (ACOS)**England and Wales**YesChronic productive coughBreathlessness and exercise limitationFrequent exacerbatorSmoking, respiratory failure, cor pulmonale, abnormal BMI and anxiety and depression**Finland**YesLow exacerbation risk: infrequent previous exacerbations, FEV~1~ ≥50% pred, no typical features of ACOSHigh exacerbation\
risk: history of exacerbations, FEV~1~ \<50% pred, no typical features of ACOSOverlap: there are features of both asthma and COPD**France**YesEpisodic dyspnoeaDaily dyspnoea on exerciseFrequent exacerbators with severe airflow obstruction despite regular bronchodilator therapy**Germany**No**Italy**YesAirflow limitationEmphysema**Poland**YesChronic bronchitis: dominant symptoms are cough and sputum productionEmphysema: dominant symptoms are dyspnoea during exercise, radiographic characteristicsFrequent exacerbator: ≥2 exacerbations treated with antibiotics and/or oral steroids within 12 months**Portugal**YesFrequent exacerbator: ≥2 exacerbations per year or ≥1 exacerbation requiring hospitalisation**Russia**YesBronchitic: blue bloater (overweight, diffuse cyanosis, warm extremities, productive cough, stocky build, wheezy, right heart failure, *etc*.)Emphysematous: pink puffer (dyspnoea, thin build, hyperinflated, quiet chest, *etc*.)Frequent exacerbator: ≥2 exacerbation per year or ≥1 exacerbation requiring hospitalisationACOS: reversibility with bronchodilator, elevated sputum eosinophils and history of asthma; minor criteria for mixed phenotype (elevated IgE and history of atopy)**Spain**YesChronic bronchitis: divided into exacerbators and nonexacerbatorsEmphysema: divided into exacerbators and nonexacerbatorsExacerbator: ≥2 exacerbations per year\
Nonexacerbator: \<2 exacerbations per yearACOS**Sweden**YesBronchitic: based on lung function evaluation (may indicate responsivity to roflumilast)Frequent exacerbator: ≥2 exacerbations per year (especially important if consistent for ≥2 years)ACOS: characteristics of both COPD and asthma[^2]

The asthma--COPD overlap syndrome (ACOS) phenotype was recognised in recommendations from the Czech Republic, Finland, Russia, Spain and Sweden. As noted earlier, this phenotype was not specifically recognised in recommendations from Germany and this was also the case for France and Italy. In the Czech Republic guidelines, the major criteria for a diagnosis of ACOS in a patient that also meets the criteria for a diagnosis of COPD were the degree of reversibility in bronchodilator testing (FEV~1~ \>15% pred and \>400 mL), exhaled nitric oxide fraction (*F*~eNO~) ≥45--50 ppb and/or elevated sputum eosinophils ≥3%, and history of asthma. In the Finnish guidelines, major diagnostic criteria for ACOS included a significant bronchodilator response (FEV~1~ \>15% pred and \>400 mL), sputum eosinophilia or elevated *F*~eNO~ (\>50 ppb), and previous symptoms compatible with asthma starting when the patient was \<40 years of age in addition to meeting the criteria for a diagnosis of COPD. The Spanish guidelines include a positive bronchodilator test (increase in FEV~1~ \>15% and \>400 mL), eosinophilia in sputum and a personal history of asthma as major criteria for ACOS. Criteria for a diagnosis of ACOS are not stated in the Polish and Russian guidelines.

The frequent exacerbator phenotype was recognised in recommendations from the Czech Republic, England and Wales, Finland, Poland, Portugal, Russia, Spain and Sweden. Those from the Czech Republic defined frequent exacerbators as those with a history of two or more exacerbations in the past year. The guidelines from Finland, Russia, Portugal and Spain defined frequent exacerbators as those who had two or more exacerbations or one or more severe exacerbation leading to hospitalisation in the previous year. The guidelines from Poland used these criteria and also included those with FEV~1~ \<50% pred as being likely to have exacerbations. Guidelines from Sweden also considered the number of exacerbations in the previous year for patient stratification. French guidelines identified patients with repeated exacerbations, mostly for the purpose of defining some treatment indications (indication for ICS + LABA combination, see later).

Treatment goals {#s3d}
---------------

Recommendations from the majority of countries identified decreasing severity of current symptoms, reducing future risk for exacerbations, slowing disease progression and/or lowering mortality as significant treatment goals. The guidelines from the Czech Republic, Finland, France, Poland, Portugal and Sweden all cited reducing symptoms, averting the natural progression of the disease, improving quality of life, enhancing physical activity, preventing complications and adverse consequences and increasing life expectancy as treatment goals. Those from Germany and Spain included improvement of symptoms, exercise capacity, quality of life and reduction of exacerbation frequency. The guidelines from Russia had short-term goals of symptom relief and improvement of exercise tolerance and quality of life and long-term goals of preventing disease progression and exacerbations and decreasing mortality. While overall treatment goals were not explicitly stated in the Italian guidelines, they did note that the main goal of pharmacotherapy for patients with COPD was bronchodilation.

Treatment selection {#s3e}
-------------------

Recommended initial pharmacotherapy was generally a short-acting β~2~-agonist (SABA) or short-acting antimuscarinic agent (SAMA) in patients with mild disease. In more symptomatic patients, a LABA or LAMA was the preferred treatment. No guideline provided precise criteria to choose between these options. The association of LABA + LAMA was an alternative choice in the Czech Republic, England and Wales, Finland, Italy, Poland, Russia, Spain and Sweden; in France, it was to be considered when a single agent did not provide satisfactory effectiveness; and it was a major choice for GOLD group C patients in Sweden. Recommendations from Poland, Portugal, Russia and Sweden stratified initial treatment on the basis of the GOLD A--D classification scheme \[[@C22]\]; and both France and Germany based treatment selection mainly on the severity of airflow obstruction according to GOLD spirometric severity stage \[[@C22]\] ([table 3](#TB3){ref-type="table"}). The French guidelines also considered the burden of dyspnoea for choosing between short-acting and long-acting bronchodilators and exacerbations in deciding whether to employ ICS + LABA combinations in patients with severe airflow obstruction. TABLE 3Preferred first treatment choice**Patient type 1Patient type 2Patient type 3Patient type 4Czech Republic^\#^**Bronchitic: standard treatment + one or more options: PDE4 inhibitor if exacerbator, mucoactive drugs or antibioticsEmphysematous: standard treatment + one or more options: theophylline, BVR, LVRS, bullectomy or α~1~-ATFrequent exacerbator: standard treatment + one or more options: PDE4 inhibitor, ICS + LABA, mucoactive drugs or antibioticsACOS: standard treatment + one or more options:\
ICS + LABA, ICS + LABA + LAMA or anti-leukotrienes**England and Wales**Breathlessness and exercise limitation: SABA or SAMAExacerbations or breathlessness and FEV~1~ ≥50% pred: LABA or LAMAExacerbations or breathlessness and\
FEV~1~ \<50%: LAMA or\
ICS + LABAPersistent exacerbations or breathlessness: ICS + LABA or LABA + LAMA if ICS declined or not tolerated or LAMA + ICS + LABA**Finland**Low risk for exacerbations: SABA or SAMALow risk for exacerbations: LABA or LAMAHigh risk for exacerbations: LAMA or ICS + LABAACOS: at least ICS + LABA or ICS + LABA + LAMA**France**GOLD 1: SABA or SAMA (or both)GOLD 2: LABA or LAMA (both if dyspnoea persists during usual exercise)GOLD 3: ICS + LABA if repeated exacerbations or LABA + LAMAGOLD 4: triple therapy (ICS + LABA + LAMA) if previous step is not sufficient**Germany**GOLD 1: avoidance of risk factors; vaccination(s); and SABAGOLD 2: add LABA(s) and rehabilitationGOLD 3: add ICS in patients with frequent exacerbationsGOLD 4: add LTOT; possible indication for surgery**Italy**Symptomatic with confirmed diagnosis of COPD, mMRC stage ≥1 and prebronchodilator FEV~1~ ≥80% pred: consider treatment with bronchodilatorsSymptomatic with confirmed diagnosis of COPD and prebronchodilator FEV~1~ \<80% pred: consider LABAIf patient /physician not satisfied: increase bronchodilator dose; add second category LABD; add ICS in frequent exacerbators**Poland**CAT \<10, FEV~1~ ≥50% pred, low exacerbation: SABA or SAMACAT ≥10, FEV~1~ ≥50% pred, low exacerbation: LABA or LAMACAT \<10, FEV~1~ \<50% pred, high exacerbation: LAMA or ICS + LABACAT ≥10, FEV~1~ \<50% pred, high exacerbation: LAMA and/or ICS + LABA**Portugal**GOLD A: SABA or SAMAGOLD B: LABA or LAMAGOLD C: LAMA or\
ICS + LABAGOLD D: LAMA and/or ICS + LABA**Russia**GOLD A: SABA or SAMAGOLD B: LABA or LAMAGOLD C: LAMA or\
ICS + LABAGOLD D: ICS + LABA, LAMA, ICS + LABA\
+ LAMA**Spain**Nonexacerbator: LAMA or LABAACOS: ICS + LABAExacerbator with chronic bronchitis: LAMA or\
ICS + LABAExacerbators with emphysema: LAMA or ICS + LABA**Sweden**GOLD A: SABA or SAMAGOLD B: LAMAGOLD C: ICS + LAMA or\
ICS + LABA + LAMAGOLD D: LAMA + LABA + ICS[^3]

Several guidelines tailored preferred treatment recommendations on the basis of patient phenotype. Guidelines from the Czech Republic indicated that bronchitic patients might require a phosphodiesterase (PDE) type 4 inhibitor, a mucoactive agent, and/or macrolide added to bronchodilator treatment and that patients with emphysema might also receive theophylline. Recommendations for patients with ACOS included ICS + LABA or ICS + LABA + LAMA (Czech Republic, Finland and Spain) and the possibility of adding a leukotriene response modifier (Czech Republic, but not supported by any clinical trial results in patients with ACOS). Recommendations for preferred therapy for frequent exacerbators included standard treatment and PDE4 inhibitor, ICS + LABA, mucoactive drugs and antibiotics (Czech Republic); ICS + LABA (France); ICS + LABA or LAMA (Finland, Spain and Poland); addition of ICS to a long-acting bronchodilator (Germany); and LAMA, ICS + LABA, LABA + LAMA or ICS + LABA + LAMA (England and Wales).

Recommendations for treatment with LABA + LAMA varied across national guidelines ([table 4](#TB4){ref-type="table"}). Combination of LABA + LAMA was listed as an alternative choice in the guidelines from Finland, France, Poland, Portugal and Spain. In Germany and Russia, LABA + LAMA combination was a first choice for treatment of specific patient subgroups, whereas in the Czech Republic combination therapy was an option for all patients. In England and Wales, a LABA + LAMA combination was recommended in patients where LABA + ICS were indicated, but ICS was declined or could not be tolerated. It may also be considered in patients with persistent breathlessness despite treatment with LAMA, LABA or LABA + ICS. None of the guidelines provided specific recommendations regarding the use of fixed-dose LABA + LAMA combinations. TABLE 4Use of long-acting β~2~-agonist (LABA) + long-acting muscarinic antagonist (LAMA) combinations and inhaled corticosteroids (ICS)**LABA + LAMAICSCzech Republic**Option for all patients; depends on severityPatient with ACOS or frequent exacerbator**England and Wales**Consider in patients indicated for ICS + LABA if ICS refused or cannot be tolerated Consider in patients with persistent breathlessness despite treatment with LAMA, LABA or ICS + LABAPatients who remain breathless or have exacerbations despite using short-acting bronchodilators and FEV~1~ \<50% pred **and** in patients with FEV~1~ ≥50% pred who remain breathless or have exacerbations despite maintenance therapy with a LABA; increased risk of pneumonia is mentioned**Finland**Alternative choicePatient belongs to high exacerbation risk group (frequent exacerbations despite the use of appropriate bronchodilator therapy, FEV~1~ \<50--70% pred) or presents with ACOS; increased risk of pneumonia is mentioned**France**GOLD stage 2 patients if there is dyspnoea during usual activities despite single long-acting bronchodilator GOLD stages 3 and 4Used only as part of fixed-dose combinations; FEV~1~ \<50% pred (\<60% pred for salmeterol/fluticasone) **and** repeated exacerbations (≥2 per year) **and** symptoms despite regular treatment with bronchodilator(s) (LABA and/or LAMA)**Germany**GOLD stage 2 and higher (possibly triple therapy and additional treatments in GOLD stages 3 and 4)FEV~1~ \<50% pred and ≥1 exacerbation treated with systemic steroids and/or antibiotics in the past year**Italy**A second long-acting bronchodilator with a complementary mechanism of action may be added if the patient and/or physician are not satisfied with the response to single-agent therapyIn symptomatic patients, with prebronchodilator FEV~1~ \<60% pred and ≥2 exacerbations per year; ICS may be added to LABA**Poland**Alternative choice≥2 COPD exacerbations treated with antibiotics/oral steroids or ≥1 hospitalisation due to COPD exacerbation within past 12 months, or FEV~1~ \<50% pred**Portugal**Alternative choiceICS are recommended in GOLD classes C and D; no specific criteria are stated for use in these classes, but frequent exacerbations should prompt augmentation of therapy**Russia**First choice in GOLD D patients\
Alternative choice in GOLD B and C patientsFrequent exacerbations, sputum eosinophilia or systemic inflammation; increased risk of pneumonia is mentioned**Spain**Alternative choice (nonexacerbator)ACOS, exacerbator phenotype despite optimal bronchodilation; increased risk of pneumonia is mentioned**Sweden**Alternative choice in GOLD B patients\
First choice in GOLD C and D patientsRepeated exacerbations or FEV~1~ \<50--60% pred[^4]

In the majority of guidelines, the criteria for the proper use of ICS were roughly similar. ICS was recommended in combination with bronchodilators in patients with FEV~1~ \<50% (or \<60%) pred, at high risk for exacerbations and/or with a history of two or more exacerbations in the previous year, as well as in those with ACOS. In patients without ACOS, ICS use was generally restricted to patients not effectively managed with bronchodilators alone, and usually to those with two or more exacerbations per year, eventually further restricted to patients with severe airflow obstruction (France) ([table 4](#TB4){ref-type="table"}).

Additional treatments were considered in all recommendations ([table 5](#TB5){ref-type="table"}). Theophylline was recommended with reservations by all countries except Italy. Roflumilast was recommended in patients with severe COPD with characteristics of chronic bronchitis and a history of exacerbations in most countries. However, this agent is not available or not reimbursed in England and Wales, France, Poland and Portugal. It is currently reimbursed in Germany, but was not available at the time the guidelines were written. Macrolides could be used as alternative treatment for stable disease in patients still experiencing exacerbations despite optimal treatment in the Czech Republic, Finland, Russia and Spain. They were not recommended for stable disease in Poland, and other countries did not provide recommendations. *N*-acetylcysteine/oral carbocisteine were both recommended in the Czech Republic, England and Wales (with caveats), Poland, Russia and Spain, but not recommended in Finland, France and Portugal. TABLE 5Additional treatments for stable chronic obstructive pulmonary disease (COPD)**TheophyllineRoflumilastMacrolide*N*-acetylcysteineOral carbocisteineCzech Republic**REC: emphysematousREC: frequent exacerbators, bronchitic, COPD and bronchiectasisREC: (option) frequent exacerbators, bronchitic, COPD and bronchiectasisREC: frequent exacerbators, bronchitic, COPD and bronchiectasisREC: frequent exacerbators, bronchitic, COPD and bronchiectasis**England and Wales**REC: after inhaled treatmentsNRNRRECNR**Finland**REC: possibly in patients with low exacerbation riskREC: in high exacerbation risk if frequent exacerbations, chronic bronchitis, and FEV~1~ \<50% predREC: for specialist use onlyNO: not for long-term useNO: not for long-term use**France**REC: only when treatment goals are not attained with inhaled treatmentsNot reimbursedNRNONO**Germany**REC: third choiceNot availableStudies not availableREC: only for viscous secretionsNR**Italy**NRREC: for patients not controlled with bronchodilators, FEV~1~ \<50% pred, ≥2 exacerbations per year and chronic bronchitisNRNRNR**Poland**REC: with qualificationsREC: not reimbursedNORECREC**Portugal**REC: only if better options cannot be usedNot availableNRNRNR**Russia**RECRECRECRECREC**Spain**REC: third-lineREC: second-lineREC: third-lineREC: second-lineREC: second-line**Sweden**NO: but may be usedRECNRNONR[^5]

Impact of comorbidities on COPD treatment decisions {#s3f}
---------------------------------------------------

Recommendations from most countries (England and Wales, France, Germany, Italy, Poland, Portugal, Spain and Sweden) did not suggest alterations in COPD treatment in patients with common comorbidities (online supplementary table S1). However, they did indicate that comorbidities should be evaluated and appropriately managed. Recommendations from Finland and Russia suggested caution/careful consideration regarding use of ICS in patients with or at risk of osteoporosis, diabetes and pneumonia; and also for high-dose β~2~-agonists in patients with cardiovascular disease.

Discussion {#s4}
==========

The European and Russian guidelines for the treatment of COPD have numerous differences when considered in detail, but they also have many general similarities with respect to both diagnosis and management of patients with this disease. There are many potential reasons for differences between guidelines, which might include differences in national healthcare systems, differences in opinions regarding cost-effectiveness of drugs, reimbursement issues and availability of medications. However, it is reasonable to suggest that one of the most important reason for differences among guidelines is the evidence available at the times when they were developed. The publication dates for the guidelines reviewed ranged from 2007 for Germany to 2015 for Finland.

The guidelines generally encourage the consideration of a diagnosis of COPD and evaluation with spirometry in symptomatic patients with risk factors, most notably tobacco smoking \[[@C9], [@C10], [@C12], [@C15]\]. However, review of these recommendations prompts the suggestion that simplification of diagnostic criteria, particularly for primary care physicians, could significantly enhance patient identification and initiation of care. This is an important issue since multiple studies from Europe have indicated that COPD is greatly underdiagnosed \[[@C1], [@C26]--[@C31]\].

There was one notable difference among countries with respect to diagnosis of COPD. The guidelines from England and Wales, Finland, France, Germany, Portugal and Russia all used FEV~1~/FVC \<70% as the spirometric criterion for a diagnosis of persistent airway obstruction and COPD, while the Czech Republic, Italy, Poland and Sweden used FEV~1~/FVC \<LLN. It has been considered that the use of the fixed ratio FEV~1~/FVC \<70% yields false negative results in individuals aged \<50 years and false positive results in those aged \>70 years \[[@C32]--[@C34]\]. However, a fixed ratio appears to be much simpler to implement, especially in non-specialised settings. For this reason, the Spanish guidelines suggest using the LLN criterion for individuals in those age groups \[[@C19], [@C35]\].

All guidelines used the same cut-offs for FEV~1~ in defining the severity of airflow obstruction. Most of the guidelines reviewed (exceptions were Germany and Italy) used a combination of measures for the determination of disease severity, impact and establishment of patient prognosis. This is consistent with results of numerous studies indicating that FEV~1~ alone does not provide the best prediction of treatment outcomes for patients with COPD \[[@C23], [@C36]--[@C38]\]. Consideration of guidelines and the clinical literature supports the view that assessment of disease severity and establishment of prognosis should be based on multiple factors, including exacerbation history, symptoms (including activity limitation) and pulmonary function \[[@C23], [@C24], [@C39]\]. This is reflected in the Spanish guidelines which employ BODE \[[@C23]\] or BODEx \[[@C24]\] for patient stratification. The utility of these two metrics for patient stratification and outcome prediction is supported by results from multiple studies. The BODE index is also mentioned for severity assessment in the French guidelines. It has been shown to be a significant predictor of exacerbations, hospitalisation, quality of life and respiratory and all-cause mortality in patients with COPD \[[@C23], [@C40]--[@C43]\]. The Spanish guidelines recommend the use of the BODEx, which replaces exercise capacity with exacerbation history, as an alternative to the BODE index in patients with GOLD stage I or II disease \[[@C19], [@C35]\]. This simplifies patient evaluation with no decrement in predictive value for mortality \[[@C24]\]. The extensive use of these composite measures and validation of their predictive value for multiple end-points supports their routine use in the initial assessment of patients with COPD.

The guidelines reviewed were in agreement regarding the existence of distinct subgroups of COPD patients, and the ACOS and frequent exacerbator "phenotypes" were generally accepted \[[@C9], [@C10], [@C12], [@C16]--[@C19], [@C21], [@C35]\]. Results from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study and other evaluations have suggested that the frequent exacerbator phenotype is relatively stable over a 3-year follow-up \[[@C44]\]. However, consideration of guidelines also indicates that it is not clear whether some COPD phenotypes are stable or can change with therapy and thus might be best considered as treatable characteristics rather than definitive traits in specific patients.

For most guidelines, patients with ACOS have disease characterised by increased reversibility of airflow obstruction, eosinophilic bronchial and systemic inflammation and increased responsivity to ICS, compared with other COPD patients. They also have more frequent exacerbations and more wheezing and dyspnoea \[[@C45]--[@C48]\]. While clear criteria for the diagnosis of ACOS have been set forth \[[@C9], [@C12], [@C19], [@C35]\], they have not been prospectively validated. In addition, a question that remains unanswered is whether ACOS should be considered as a distinct entity or rather as concomitant diseases that overlap \[[@C49]\].

There also has been considerable discussion regarding whether subgroups of patients with different clinical characteristics should be considered as distinct phenotypes and whether or not this term is useful for patient description, especially as drivers for treatment decisions \[[@C20], [@C35], [@C50]\]. Consideration of patient subgroups with COPD is further complicated by the fact that many have multiple comorbid conditions, including cardiovascular disease \[[@C51]\], lung cancer \[[@C52]\], frequent respiratory tract infections \[[@C53]\], osteoporosis \[[@C54]\], diabetes \[[@C55]\], metabolic syndrome \[[@C56]\] and psychiatric disease \[[@C57]\]. The guideline for England and Wales is innovative in advocating a simultaneous multidimensional assessment and management approach that includes comorbidities/systemic effects of COPD. There is general recognition that comorbidities should be integrated into guidelines developed for the management of patients with COPD \[[@C58]\].

There was general good agreement between guidelines with respect to the selection of preferred therapy in patients with different disease severities. However, the selection of "initial" therapy by a pulmonologist is complicated by the fact that most COPD patients are initially managed by general practitioners prior to referral and there is little evidence-based guidance for treatment selection in post-referral patients who have already been treated. Most patients with COPD are symptomatic by the time they are referred to a pulmonologist and should therefore receive treatment with long-acting bronchodilators. At present, we do not have evidence that provides a basis for stepping up or down treatment in patients with COPD and research addressing these questions is greatly needed.

More information is also needed regarding the benefits of a LABA + LAMA combination *versus* either agent alone. Results from several studies have made clear that combination of LABA + LAMA provides improvements in pulmonary function significantly greater than those achieved with monotherapy \[[@C59]--[@C61]\]. There is a growing body of evidence supporting the benefits of LABA + LAMA therapy *versus* single agents for reducing symptoms and decreasing the frequency of exacerbations \[[@C59]--[@C63]\], but more information is awaited about the comparison of LABA + LAMA *versus* LABA + ICS for the prevention of exacerbations in high-risk patients.

Inhaled corticosteroids are effective in patients with ACOS \[[@C64], [@C65]\], and they have a significant benefit in decreasing exacerbations and reducing symptom severity in other groups of COPD patients \[[@C66], [@C67]\]. However, there are some risks of significant side-effects (*e.g.* pneumonia) associated with ICS use \[[@C68]--[@C70]\], which must be considered in any treatment recommendations regarding these agents. Selection of candidates for ICS treatment would be facilitated by the availability of biomarkers predicting effectiveness (*e.g.* elevated sputum \[[@C64], [@C71]\] or blood eosinophils \[[@C72]\]), but more research is needed in this "hot topic" area.

Guidelines for diagnosis, assessment and management of patients with COPD generally lack a formal definition of disease control that takes into account COPD severity at the initiation of treatment and which can be used to evaluate efficacy of therapy. It is reasonable to suggest that such a definition should be included in treatment recommendations. S[oler-]{.smallcaps}C[ataluña]{.smallcaps} *et al.* \[[@C25]\] have set forth criteria for control of disease that consider both impact of disease, as measured by instruments such as the CAT or CCQ, and stability, as reflected by an absence of exacerbations and no deterioration in questionnaire results. Using this approach, treatment is intensified or decreased, as appropriate to maintain stability and low impact \[[@C25]\]. Addition of criteria for longitudinal patient assessment and adjustment of therapy may be a useful addition to treatment guidelines.

Guidelines for the treatment of any disease have little meaning unless they are integrated into clinical practice \[[@C73]\]. Results from multiple surveys indicate that actual treatment for many patients with COPD may not be consistent with available treatment recommendations. A recent analysis of prescribing patterns in 24 957 patients revealed that COPD was not treated according to GOLD and National Institute for Health and Care Excellence recommendations in the UK primary-care setting, with significant proportions of patients receiving no treatment despite experiencing symptoms \[[@C26]\]. Interestingly, most COPD patients received ICS irrespective of severity of airflow limitation, asthma diagnosis and exacerbation history, whereas many patients on treatment were still symptomatic \[[@C26]\]. An observational study which included information from 4094 patients with COPD treated in Italy also indicated poor adherence to GOLD treatment recommendations, with 62.1% of the patients receiving pharmacotherapy that was inappropriate for their disease severity \[[@C74]\]. An evaluation of 1355 patients with COPD in the Czech Republic indicated that 32.8% of cases were misclassified according to GOLD categories. Furthermore, 15.4% of patients received ICS unnecessarily, whereas in 15.8% of cases ICS were erroneously omitted \[[@C75]\]. In a French cohort study, ICS were prescribed outside their indications in ∼75% of patients if the "old" GOLD guidelines were taken as the reference, and in one-third when considering the new GOLD document \[[@C76], [@C77]\]. This study also underlined the high proportion of patients on triple therapy, which is supported by only a few studies and contradicted by others \[[@C78]--[@C80]\].

Physicians\' reports of their own practice patterns also indicate variability regarding adherence to and knowledge of treatment guidelines. A survey of 1307 primary-care physicians and respiratory specialists who regularly managed patients with COPD, emphysema or chronic bronchitis indicated good awareness of guidelines and frequent use of recommended diagnostic practices. However, there were significant deviations from guideline-recommended treatment. Physicians reported using spirometry routinely (primary-care physicians 82% and respiratory specialists 100%) to diagnose COPD and frequently included validated patient-reported outcome measures (primary-care physicians 67% and respiratory specialists 81%). The percentages of primary-care physicians and respiratory specialists providing first- or second-choice treatment consistent with the GOLD recommendations for a type B patient were 38% and 67%, respectively. Those for type C patients were 40% and 38%, respectively and those for type D patients were 57% and 58%, respectively \[[@C81]\]. In contrast, a survey of 590 respiratory specialists in Germany indicated good knowledge of approaches to COPD diagnosis and classification as well as treatment selection for patients with moderate or severe disease \[[@C82]\].

The limited adherence to COPD treatment guidelines may reflect issues that are not fully addressed due to insufficient information available from controlled clinical trials \[[@C8]\] and possibly also by the view that they reflect greater clinical efficacy in controlled trials than treatment effectiveness achievable in broad patient populations being managed in routine care in real-world settings \[[@C83]\].

Providing concise and succinct treatment recommendations relevant for both general and specialist physicians may improve their employment for guidance of patient management. The ERS has noted the importance of trustworthy documents to guide patient management and have established a guidelines working group to facilitate development, dissemination and implementation of guidelines \[[@C7]\]. However, it is also recognised that the methodology involved in the development of such guidelines requires specialised knowledge (*e.g.* application of the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) criteria to information providing the basis for the guidelines) and is time consuming and very costly \[[@C84]\]. A potentially efficient approach for the development of COPD treatment guidelines may be initial formulation at the international level and adaptation based on the needs and resources in each country. This suggestion is consistent with the ERS proposal that scientific societies should work together and establish panels to provide appropriate guidance regarding respiratory disease to physicians and patients \[[@C7]\].

In conclusion, the review of guidelines indicated several areas that should be addressed and questions that need to be answered to facilitate diagnosis and treatment of COPD (online supplementary table S2): 1) recommendations should increase suspicion of COPD among primary care physicians, who are usually the first to encounter these patients; 2) there are distinct constellations of patient characteristics that may be useful for establishment of prognosis and guiding treatment selection, but it is not clear whether they should be considered as permanent phenotypes or treatable characteristics; 3) better guidance is needed for patient treatment (stepping up or down treatment); 4) SABAs and SAMAs are suboptimal as regular treatment for symptomatic individuals with COPD, since long-acting bronchodilators are superior; 5) more information is needed about the long-term efficacy and safety of LABA + LAMA combinations *versus* single agents and it is most important to understand their efficacy on symptoms and exacerbations; and 6) both the potential risks and benefits should guide selection of treatments (this seems particularly important for ICS).

It is important that guidelines be updated regularly to keep pace with that of research on the diagnosis, characterisation and management of patients with COPD. This is becoming increasingly difficult due to the vast effort, time and expense associated with guideline development \[[@C85]\] and the growing abundance of clinically relevant literature. Maintaining good alignment of treatment recommendations and clinical research results might be facilitated by simple and concise recommendations that would complement detailed guidelines and could be rapidly updated as important results from clinical trials become available.
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[^1]: GOLD: Global Initiative for Chronic Obstructive Lung Disease; mMRC: modified Medical Research Council; CAT: COPD assessment test; FEV~1~: forced expiratory volume in 1 s; FVC: forced vital capacity; BMI: body mass index; NICE: National Institute for Health and Care Excellence; *P*~aO~2~~: arterial oxygen tension; CCQ: clinical COPD questionnaire. ^\#^: the guidelines for England and Wales also assess *P*~aO~2~~; ^¶^: provides a separate tool for assessing severity of obstruction according to GOLD strategy as well as assessing the severity of full clinical presentation.

[^2]: COPD: chronic obstructive pulmonary disease; ACOS: asthma--COPD overlap syndrome; BMI: body mass index; FEV~1~: forced expiratory volume in 1 s. ^\#^: recommendations also include COPD + bronchiectasis and pulmonary cachexia phenotypes.

[^3]: PDE: phosphodiesterase; BVR: bronchoscopic volume reduction; LVRS: lung volume reduction surgery; α~1~-AT: α~1~-antitrypsin; ICS: inhaled corticosteroid; LABA: long-acting β~2~-agonist; ACOS: asthma--chronic obstructive pulmonary disease (COPD) overlap syndrome; LAMA: long-acting muscarinic antagonist; SABA: short-acting β~2~-agonist; SAMA: short-acting muscarinic antagonist; FEV~1~: forced expiratory volume in 1 s; GOLD: Global Initiative for Chronic Obstructive Lung Disease; LTOT: long-term oxygen therapy; mMRC: modified Medical Research Council; LABD: long-acting bronchodilator; CAT: COPD assessment test. ^\#^: recommendations for standard treatments include inhaled bronchodilators (LABA, LAMA, ultra-LABA and ultra-LAMA), pulmonary rehabilitation, vaccination, education, long-acting muscarinic antagonist, inhalation training, dietary changes, comorbidity treatment and risk elimination. Patients with COPD and bronchiectasis receive a PDE4 inhibitor, mucoactive drugs, antibiotics and physiotherapy; and those with pulmonary cachexia receive rehabilitation and nutritional support.

[^4]: ACOS: asthma--chronic obstructive pulmonary disease (COPD) overlap syndrome; FEV~1~: forced expiratory volume in 1 s; GOLD: Global Initiative for Chronic Obstructive Lung Disease.

[^5]: REC: recommended; NR: no recommendation; FEV~1~: forced expiratory volume in 1 s; NO: not recommended.
